The incremental net monetary benefit of higher-valent pneumococcal conjugate vaccines for adults: a systematic review and meta-analysis of economic evaluations
Higher-valent PCVs appear cost-effective in most adult populations and settings, especially in high-income countries and from the healthcare perspective. This meta-analysis provides a rigorous quantitative synthesis to support vaccine policy decisions.
Authors
- Jeffrey Vietri (ORCID: https://orcid.org/0000-0002-5610-3098)
- H Lee (ORCID: https://orcid.org/0000-0003-3956-9758)
- Jeong‐Yeon Cho (ORCID: https://orcid.org/0000-0003-1351-5006)
- Euan Dawson
Institutions
- Pfizer (United States) (US)
- University of Utah (US)
- VA Salt Lake City Healthcare System (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1080/13696998.2025.2565902
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00